Home » Stocks » ONCY

Oncolytics Biotech Inc. (ONCY)

Stock Price: $2.72 USD -0.17 (-5.88%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 117.48M
Revenue (ttm) n/a
Net Income (ttm) -33.12M
Shares Out 22.14M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $2.72
Previous Close $2.89
Change ($) -0.17
Change (%) -5.88%
Day's Open 2.84
Day's Range 2.70 - 2.88
Day's Volume 1,039,441
52-Week Range 0.98 - 4.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Insider Monkey - 1 month ago

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13...

Seeking Alpha - 2 months ago

Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

SAN DIEGO, and CALGARY, AB, Nov. 11, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter en...

PRNewsWire - 2 months ago

- Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET SAN DIEGO and CALGARY, AB, Nov. 6, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ...

PRNewsWire - 4 months ago

SAN DIEGO and CALGARY, Alberta, Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Calif. and CALGARY, AB, Aug.

Seeking Alpha - 5 months ago

Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

SAN DIEGO and CALGARY, Alberta, June 25, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TN...

PRNewsWire - 7 months ago

SAN DIEGO, Calif. and CALGARY, Alberta, June 15, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-onc...

PRNewsWire - 7 months ago

SAN DIEGO, California and CALGARY, Alberta, June 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored...

PRNewsWire - 7 months ago

SAN DIEGO and CALGARY, Alberta, May 29, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vi...

PRNewsWire - 7 months ago

SAN DIEGO and CALGARY, Alberta, May 26, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vi...

PRNewsWire - 8 months ago

SAN DIEGO and CALGARY, Alberta, May 14, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vi...

Seeking Alpha - 10 months ago

Oncolytics Biotech's (ONCY) CEO Matt Coffey on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.

Zacks Investment Research - 11 months ago

While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.

Other stocks mentioned: NVAX
Seeking Alpha - 1 year ago

Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Oncolytics.

Seeking Alpha - 1 year ago

Oncolytics Biotech Inc. (ONCY) CEO Dr.

About ONCY

Oncolytics Biotech, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negati... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 1999
CEO
Dr. Matthew C. Coffey
Stock Exchange
NASDAQ
Ticker Symbol
ONCY
Full Company Profile

Financial Performance

Financial Statements